GlassScriptPhysician profile
Joel C Milligan
NPI 1093829640
$8,915.08
in general payments reported to CMS, 2019-2025
54 companies · $1,268 in 2025
The $1,268 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,213 · 2020: $872 · 2021: $1,598 · 2022: $1,213 · 2023: $1,406 · 2024: $1,345 · 2025: $1,268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,019.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,597.17 | 2019-2025 | |
| Pfizer INC. | $819.67 | 2019-2025 | |
| Glaxosmithkline, LLC. | $686.94 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $587.19 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Merck Sharp & Dohme LLC | $451.55 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Amarin Pharma, INC. | $380.98 | 2019-2022 | |
| Amgen INC. | $362.61 | 2019-2025 | Otezla, Repatha, Repatha |
| Otsuka America Pharmaceutical, INC. | $334.81 | 2021-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $255.35 | 2019-2025 | Farxiga |
| Lilly USA, LLC | $251.75 | 2019-2025 | Mounjaro, Jardiance |
| Novartis Pharmaceuticals Corporation | $251.43 | 2019-2022 | |
| Allergan, INC. | $239.82 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $223.47 | 2021-2025 | |
| Novo Nordisk INC | $173.98 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Dexcom, INC. | $171.89 | 2022-2025 | Dexcom G6 Transmitter |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Milligan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.